Difference between revisions of "Midostaurin (Rydapt)"
Jump to navigation
Jump to search
(Created page with "In clinical trials Category:Kinase inhibitors Category:FLT3 inhibitors Category:Investigational") |
m |
||
| Line 1: | Line 1: | ||
| − | + | ==Mechanism of action== | |
| + | Small molecule FLT3 tyrosine kinase inhibitor. | ||
| + | |||
| + | ==Preliminary data== | ||
| + | # Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005 Jan 1;105(1):54-60. Epub 2004 Sep 2. [http://bloodjournal.hematologylibrary.org/content/105/1/54.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/15345597 PubMed] | ||
| + | <!-- Presented in part at the 45th Annual Meeting of the American Society of Hematology, December 6-9, 2003, San Diego, CA. --> | ||
| + | # Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010 Oct 1;28(28):4339-45. Epub 2010 Aug 23. [http://jco.ascopubs.org/content/28/28/4339.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/20733134 PubMed] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:FLT3 inhibitors]] | [[Category:FLT3 inhibitors]] | ||
| + | [[Category:KIT inhibitors]] | ||
| + | [[Category:PDGFR inhibitors]] | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
Revision as of 15:35, 10 June 2014
Mechanism of action
Small molecule FLT3 tyrosine kinase inhibitor.
Preliminary data
- Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005 Jan 1;105(1):54-60. Epub 2004 Sep 2. link to original article PubMed
- Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010 Oct 1;28(28):4339-45. Epub 2010 Aug 23. link to original article PubMed